130results about "Integrin superfamily" patented technology

Proteins with anti-angiogenic properties are disclosed, and fragments thereof, and methods of using those proteins and fragments to inhibit or promote angiogenesis.

The invention relates to disulfide-rich dimer molecules which inhibit binding of α4β7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, and show high selectivity against α4β1 binding.

The invention relates to anti-α2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of α2 integrin and inhibit the interaction of α2β1 integrin with collagen. Also disclosed are therapeutic uses of anti-α2 integrin antibodies in treating α2β1-mediated disorders, including anti-α2 integrin antibodies that bind to α2 integrin without activating platelets.

The present disclosure provides isolated integrin αL polypeptides, such as α7 helix polypeptides from the alpha I domain of integrin. Such polypeptides inhibit the interaction between integrin and gp96, thereby inhibiting gp96 activity. Such inhibition can be used to prevent cancer cell growth, cancer metastasis and / or inflammation.

The invention relates to disulfide-rich dimer molecules which inhibit binding of α4β7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, and show high selectivity against α4β1 binding.

The invention relates to thioether monomer and dimer peptide molecules which inhibit binding of α4β7 to the mucosal addressing cell adhesion molecule (MAdCAM) in vivo.

The present invention provides a recombinant adenovirus comprising coat proteins that lack native binding. In particular, the present invention provides a recombinant adenovirus comprising a penton base protein and a fiber protein, wherein the penton base protein and the fiber protein lack native binding. The present invention further provides a recombinant adenovirus comprising (a) a penton base protein that lacks native binding and (b) a nonnative amino acid sequence that binds a cell-surface binding site.

The present invention provides methods of making α4β7 peptide monmer and dimer antagonists. Methods of the present invention include solid phase and solution phase methods, as well as synthesis via condensation of smaller peptide fragments. Methods of the present invention further include methods directed to the synthesis of peptides comprising one or more penicillamine residues.

A marker for mesenchymal stem cells (MSC) is provided, comprising an integrin alpha 10 chain and / or an integrin alpha 11 chain expressed on the cell surface of or intracellular in a MSC. The marker is used in methods for identification of mammalian MSC and in methods for isolation of MSC. Also included are isolated cellular populations of mammalian MSC and a cellular composition comprising the latter. Moreover, uses of said marker for isolation, modulation and identification mammalian MSC are provided.

Methods and compositions comprising antagonists of αvβ6 are provided for the treatment of acute lung injury fibrosis.

The present disclosure provides methods for identifying compositions which increase the expression of α7 integrin protein in muscle cells of dystrophy patients. The present disclosure further provides compositions and sequences for the diagnosis, genetic therapy of certain muscular dystrophies, especially muscular dystrophy resulting from a deficiency in an α7 integrin protein or a dystrophin protein or a combined deficiency in dystrophin and utrophin, and methods and compositions for the identification of compounds which increase expression of the α7 integrin. Expression of the integrin αBX2 polypeptide in muscle cells results in better physical condition in a patient or an animal lacking normal levels of dystrophin or dystrophin and utrophin.

The present disclosure provides compositions and sequences for the diagnosis, genetic therapy of certain muscular dystrophies, especially muscular dystrophy resulting from a deficiency in dystrophin protein or a combined deficiency in dystrophin and utrophin, and methods and compositions for the identification of compounds which increase expression of the α7 integrin. Expression of the integrin αBX2 polypeptide in muscle cells results in better physical condition in a patient or an animal lacking normal levels of dystrophin or dystrophin and utrophin. The present disclosure further provides immunological and nucleic acid based methods for the diagnosis of scapuloperoneal muscular dystrophy, where there is a reduction in or absence of α7A integrin expression in muscle tissue samples and normal levels of laminin-2 / 4 in those same samples. The present disclosure further provides methods for identifying compositions which increase the expression of α7 integrin protein in muscle cells of dystrophy patients.

The invention generally relates to fusion proteins comprising a rhodostomin variant having an RGD motif variant 48ARLDDL53, wherein the rhodostomin variant is conjugated with a variant of Human Serum Albumin (HSA). The invention also relates to the use of these fusion proteins for treatment and prevention of αvβ3 integrin-associated diseases.

The present invention provides an isolated polypeptide capable of binding to aCAM-1, comprising the integrin (XL I domain or biologically active portion thereof, wherein one or more residues is substituted, wherein the substituted polypeptide binds ICAM-I at a higher affinity than wild type integrin CCL protein. The invention provides a method for inhibiting ICAM-I and a pharmaceutical composition comprising an integrin (XL I domain polypeptide or biologically active portion of the polypeptides. The invention also provides a method of treating or preventing an LFA-I mediated ICAM-1 associated disease such as inflammation, artherosclerosis, allograft rejection, diabetes, T-cell mediated sensitization reaction, psoriasis, HIV infection, or rheumatoid arthritis.

The invention provides human and murine isolated nucleic acid molecules, designated A259 nucleic acid molecules, which encode secreted proteins with homology to integrin α subunits, specifically to integrin α10. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially carcinomas, such as ovarian carcinoma. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against cancer.

Disclosed are chimeric antigen receptors (CAR) specific to αvβ6 integrin which is uniquely expressed in a wide variety of cancers. Also disclosed are vectors to express the CAR and methods to use the CAR to treat patients suffering from cancer. The instant disclosure provides a CAR comprising a binding domain specific to αvβ6 integrin. In various exemplary embodiments, the αvβ6 specific binding domain comprises a sequence as defined by SEQ ID NOs. 1-12. In some embodiments, the CAR comprises one or more intracellular domains comprising 4-1 BB domain, CD3ζ domain, and CD28 domain. In some embodiments, the αvβ6 binding domain is fused to an Fc region by a glycine-serine linker. In these and other embodiments, the Fc region is substantially similar to an lgG4 or an lgG1 Fc region.

Novel cyclic peptides having VLA-4 adhesion inhibiting activity, and their application as therapeutic agents for inflammatory disease, for example allergic inflammatory disease, or hepatitis. Cyclic peptides represented by formula (I)where A and F may be the same or different, and are both selected from L- or D-form Cys, homo-Cys, Pen and Mpr, or both from the group comprising Asp, Glu, Aad, Dpr, Dab and Orn, B is selected from L-or D-form Ala, Ala(t-Bu), Val, Leu, Ile, aIle, Abu, Nle, Nva, Tle, Cha, Chg, Phe, Phg, Trp, Ala(3-Bzt), Ala(1-Naph), Ala(2-Naph), Ala(2-Pyr), Ala(2-Qui), His, Thi, Ala(4-Thz), 2-Abz, Pro, homo-Pro and Tic, C is selected from L-form Asp analogues, Gle analogues, Aad analogues, Asn analogues, Gln analogues, Ser, Ser(OMe), homo-Ser, Dpr, Dab, Orn, Met, Met)O), Met(O2), aIle, Nle, Nva, Chg, Phg, Tyr and Tle, D is selected from L- or D-form Tyr, Ser, homo-Ser, Leu, Ile, AIle, Nle, Nva, Chg, Cha, Val, Ala(t-Bu), Abu, Tle, Ala, Phg, homo-Phe, Phe, Ala(2-Naph), Ala(2-Pyr), Ala(3-Bzt), Ala(1-Naph), Ala(2-Qui), Thi, Ala(4-Thz), 2-Abz, Trp and His, E is selected from L- or D-form Leu, Ile, aIle, Nle, Nva, Chg, Cha, Tle, Phg, homo-Phe, Ala(2-Naph), Ala(2-Pyr), Ala(3-Bzt, Ala(1-Naph), Ala(2-Qui), Thi, Ala(4-Thz), 2-Abz and His, G represents a disulphide bond or amide bond, R1 represents hydrogen or an acyl group, and R2 is hydrogen or an alkyl group, or salts thereof, and to their use in treating inflammatory diseases.

The present invention is directed to protocells, which have a core and a lipid bilayer surrounding the core, with at least one CD47 molecule or an active fragment thereof in or conjugated to the lipid bilayer. The CD47 present on the lipid bilayer allows the protocell to evade phagocytosis by macrophages, and can be conjugated to the lipid bilayer via a crosslinker. The protocell can be loaded with a diagnostic or therapeutic cargo, such as a polypeptide, a nucleic acid, or a drug. The protocell can also include a targeting species for targeted delivery of the cargo to a cell. The protocell can also include an endosomolytic peptide, which promotes endosomal escape after uptake by the targeted cell. The protocells with CD47 on the lipid bilayer provide better circulation after in vivo administration compared to protocells without CD47, and are therefore particularly useful as a cargo delivery vehicle.

The present disclosure relates to compositions and methods for targeting expression of exogenous genes to platelets. In particular, the present disclosure relates to treatment of hemophilia and other diseases and conditions by targeting expression of exogenous agents (e.g., clotting factors) to platelets.

There is provided a method for inhibiting growth and / or proliferation of a cancer cell. The method comprises treating a cancer cell with an effective amount of a polypeptide providing a cytoplasmic binding domain of a β integrin subunit for binding of ERK2 to inhibit at least one protein kinase, other than a MAP kinase, in a cell activation pathway of the cancer cell. The protein kinases inhibited by the polypeptide may be selected from the group consisting of c-Raf, MEK 1 and kinases in the Src, PI3K, PKB / AKT and PKC families. Methods for the prophylaxis and treatment of cancer are also provided.